Literature DB >> 16616379

LRRK2 in Parkinson's disease: protein domains and functional insights.

Ignacio F Mata1, William J Wedemeyer, Matthew J Farrer, Julie P Taylor, Kathleen A Gallo.   

Abstract

Parkinson's disease (PD) is the most common motor neurodegenerative disease. Mutations in the gene encoding leucine-rich repeat kinase 2 (LRRK2) have been linked recently with autosomal-dominant parkinsonism that is clinically indistinguishable from typical, idiopathic, late-onset PD. Thus, the protein LRRK2 has emerged as a promising therapeutic target for treatment of PD. LRRK2 is extraordinarily large and complex, with multiple enzymatic and protein-interaction domains, each of which is targeted by pathogenic mutations in familial PD. This review places the PD-associated mutations of LRRK2 in a structural and functional framework, with the ultimate aim of deciphering the molecular basis of LRRK2-associated pathogenesis. This, in turn, should advance our understanding and treatment of familial and idiopathic PD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16616379     DOI: 10.1016/j.tins.2006.03.006

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  175 in total

1.  Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant.

Authors:  Veronique Daniëls; Renée Vancraenenbroeck; Bernard M H Law; Elisa Greggio; Evy Lobbestael; Fangye Gao; Marc De Maeyer; Mark R Cookson; Kirsten Harvey; Veerle Baekelandt; Jean-Marc Taymans
Journal:  J Neurochem       Date:  2011-01       Impact factor: 5.372

2.  Association between Parkinson's disease and G2019S and R1441C mutations of the LRRK2 gene.

Authors:  Xiao-Xia Li; Qin Liao; Huan Xia; Xin-Ling Yang
Journal:  Exp Ther Med       Date:  2015-07-27       Impact factor: 2.447

3.  Effective long-term subthalamic stimulation in PARK8 positive Parkinson's disease.

Authors:  Sorin Breit; T Wächter; D Schmid-Bielenberg; D Weiss; P Leitner; T Nägele; D Freudenstein; T Gasser; R Krüger
Journal:  J Neurol       Date:  2010-02-23       Impact factor: 4.849

4.  The LRRK2 Gly2385Arg variant is associated with Parkinson's disease: genetic and functional evidence.

Authors:  E K Tan; Y Zhao; L Skipper; M G Tan; A Di Fonzo; L Sun; S Fook-Chong; S Tang; E Chua; Y Yuen; L Tan; R Pavanni; M C Wong; P Kolatkar; C S Lu; V Bonifati; J J Liu
Journal:  Hum Genet       Date:  2006-09-30       Impact factor: 4.132

5.  Identification of potential protein interactors of Lrrk2.

Authors:  Justus C Dächsel; Julie P Taylor; Su San Mok; Owen A Ross; Kelly M Hinkle; Rachel M Bailey; Jacob H Hines; Jennifer Szutu; Benjamin Madden; Leonard Petrucelli; Matthew J Farrer
Journal:  Parkinsonism Relat Disord       Date:  2007-04-02       Impact factor: 4.891

6.  Leucine-rich repeat kinase 1: a paralog of LRRK2 and a candidate gene for Parkinson's disease.

Authors:  Julie P Taylor; Mary M Hulihan; Jennifer M Kachergus; Heather L Melrose; Sarah J Lincoln; Kelly M Hinkle; Jeremy T Stone; Owen A Ross; Robert Hauser; Jan Aasly; Thomas Gasser; Haydeh Payami; Zbigniew K Wszolek; Matthew J Farrer
Journal:  Neurogenetics       Date:  2007-01-16       Impact factor: 2.660

7.  Redox proteomics analyses of the influence of co-expression of wild-type or mutated LRRK2 and Tau on C. elegans protein expression and oxidative modification: relevance to Parkinson disease.

Authors:  Fabio Di Domenico; Rukhsana Sultana; Andrew Ferree; Katelyn Smith; Eugenio Barone; Marzia Perluigi; Raffaella Coccia; William Pierce; Jian Cai; Cesare Mancuso; Rachel Squillace; Manfred Wiengele; Isabella Dalle-Donne; Benjamin Wolozin; D Allan Butterfield
Journal:  Antioxid Redox Signal       Date:  2012-03-20       Impact factor: 8.401

8.  A QUICK screen for Lrrk2 interaction partners--leucine-rich repeat kinase 2 is involved in actin cytoskeleton dynamics.

Authors:  Andrea Meixner; Karsten Boldt; Marleen Van Troys; Manor Askenazi; Christian J Gloeckner; Matthias Bauer; Jarrod A Marto; Christophe Ampe; Norbert Kinkl; Marius Ueffing
Journal:  Mol Cell Proteomics       Date:  2010-09-27       Impact factor: 5.911

9.  (G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD.

Authors:  C-Y Chen; Y-H Weng; K-Y Chien; K-J Lin; T-H Yeh; Y-P Cheng; C-S Lu; H-L Wang
Journal:  Cell Death Differ       Date:  2012-04-27       Impact factor: 15.828

10.  Haplotype analysis of Lrrk2 R1441H carriers with parkinsonism.

Authors:  Owen A Ross; Cleanthe Spanaki; Alida Griffith; Chin-Hsien Lin; Jennifer Kachergus; Kristoffer Haugarvoll; Helen Latsoudis; Andreas Plaitakis; Joaquim J Ferreira; Cristina Sampaio; Vincenzo Bonifati; Ruey-Meei Wu; Cyrus P Zabetian; Matthew J Farrer
Journal:  Parkinsonism Relat Disord       Date:  2008-10-26       Impact factor: 4.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.